Doubts lead Australia's TGA to take stock of CE-marking by 8 EU notified bodies
This article was originally published in Clinica
Australia's Therapeutic Goods Administration has signaled its distrust of the eight European medical device notified bodies whose business practices were questioned in a 2012 investigative study in the BMJ on the failings of the EU notified body system.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.